The development of novel biomarker and treatment for renal cell carcinoma based on the assessment by FDG PET/CT

• Project/Area Number: 25462494
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Yokohama City University
• Principal Investigator: NAKAIGAWA Noboru 横浜市立大学, 医学(系)研究科(研究院), 准教授 (00237207)
• Co-Investigator(Kenkyū-buntansha): YAO Masahiro 横浜市立大学, 医学研究科, 教授 (00260787)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 腎細胞癌 / 血液マーカー / 治療効果判定 / 分子標的治療 / FDG PET/CT / 進行性腎細胞癌 / 予後予測マーカー / 進行性腎癌

Outline of Final Research Achievements

We previously reported the possibility of FDG PET/CT as an imaging biomarker to assess the response of renal cell carcinoma (RCC) to molecular-targeted therapy simultaneously, which was difficult to judge by conventional computed tomographic scanning. FDG PET/CT has some problems including cost and radiation exposure, and the blood biomarker which can be examined easily and safely was desired. In this study, we isolated the blood biomarker to assess the response of renal cell carcinoma to molecular-targeted therapy, by analyzing the blood samples form the patients with RCC treated by molecular-targeted therapy and monitored by FDG PET/CT.

Research Products

• [Journal Article] FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. (2016)
  • Author(s): Nakaigawa N, Kondo K, Tateishi U, Minamimoto R, Kaneta T, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Kubota Y, Inoue T, Yao M.
  • Journal Title: BMC Cancer Volume: 16 Issue: 1 Pages: 67-67
  • DOI: 10.1186/s12885-016-2097-4
  • Peer Reviewed / Open Access
• [Journal Article] Presurgical downstaging of vena caval tumor thrombus in advanced clear cell renal cell carcinoma using temsirolimus. (2013)
  • Author(s): Sano F, Makiyama K, Tatenuma T, Sakata R, Yamanaka H, Fusayasu S, Nakayama T, Nakaigawa N, Yao M, Kubota Y
  • Journal Title: Int J Urol. Volume: 20 Pages: 637-639
  • NAID: 10031177717
  • Peer Reviewed
• [Patent(Industrial Property Rights)] 「腎細胞癌の薬物療法に対する効果判定を目的とした血中マーカー」（仮称） (2015)
  • Inventor(s): 中井川昇 上野大樹 矢尾正祐
  • Industrial Property Rights Holder: 中井川昇 上野大樹 矢尾正祐
  • Industrial Property Rights Type: 特許
  • Filing Date: 2015-10-14